Compare ACM Research Inc (ACMR) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACM Research Inc vs BioNTech SE - ADR — how do they compare? ACM Research Inc trades at $98.05 (market cap $6.54B), while BioNTech SE - ADR trades at $92.85 (market cap $23.84B). The key difference: BioNTech SE - ADR is far larger — about 3.6× ACM Research Inc's market cap, and ACM Research Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| ACMR | BNTX | |
|---|---|---|
Market Cap | $6.54B | $23.84B |
Sector | Technology | Health |
52-Week High | $126.89 | $119.34 |
52-Week Low | $23.92 | $83.89 |
Enterprise Value | $5.61B | $7.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACMR trades at $98.52, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $110. Recent earnings showed a Q1 2026 beat but misses in prior quarters. Revenue grew to $901 million in 2025, though net income margins are under pressure. The stock has experienced volatility, with news highlighting semiconductor sector catalysts and a GF Score of 82 (GuruFocus, June 25, 2026).
Outlook is positive with 80% analyst buy ratings and semiconductor demand tailwinds, but risks include earnings inconsistency, high valuation multiples, and negative operating cash flow. Investors should weigh growth potential against execution risks in a competitive market.
BioNTech (BNTX) trades at $94.29, down 3.34% on the day, as the company navigates its transition from COVID-19 vaccine dominance to oncology focus. The stock shows a bullish technical signal with strong analyst support (87.5% buy ratings) and a $130.83 consensus price target. However, fundamental challenges persist with negative net income margins (-44.64%) and declining revenues from pandemic peak levels, offset by a robust $16.78 billion cash position and ongoing $1 billion share repurchase program.
The outlook balances promising oncology pipeline developments against near-term profitability challenges. Investment opportunity lies in BioNTech's cash-rich balance sheet and advancing cancer therapeutics, while risks include execution uncertainty in the therapeutic transition, manufacturing restructuring costs, and competitive pressure in the oncology space. The stock presents a high-risk, high-reward proposition for investors betting on successful pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACM Research Inc
ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.
Read more on ACMR →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
